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Letters to the Editor
The Role of Cryptococcal Antigen Assay in Diagnosis and Monitoring
of Cryptococcal Meningitis
In a recent paper evaluating the significance of cryptococcal
antigen test results for 29 Chinese human immunodeficiency
virus (HIV)-negative patients affected by cryptococcal menin-
gitis, Lu and colleagues (8) showed in all patients a decrease of
antigen titer from the baseline following antifungal therapy
and suggested that a decrease can be used to monitor antifun-
gal therapy efficacy but cannot be used as an index of cure. We
have reviewed our experience with 66 HIV-positive patients
out of 118 with cryptococcal meningitis for whom at least three
serial determinations (at baseline, day 7, and day 14) of cryp-
tococcal antigen tests on cerebrospinal fluid (CSF) were avail-
able (1). A total of 440 determinations (range, 3 to 28 antigen
determinations; median, 5 antigen determinations) were avail-
able, and for 55 patients the last determination was considered
(median, 13 weeks; range, 2 to 84 weeks). In Fig. 1 is depicted
the kinetics of CSF cryptococcal antigen together with the
results of CSF culture. Overall, 53 patients (80%) showed a
decrease of CSF antigen titer from the baseline (7 of whom
had negative results), as follows: 27 cases of 1 to 3 dilutions, 16
cases of 4 to 6 dilutions, and 10 cases of 7 or more dilutions.
However, 13 out of 15 of these patients for whom postmortem
examination was available, despite evidence of several intravi-
tam negative CSF cultures, still had cryptococcal meningitis or
disseminated disease at autopsy (demonstrated by histopathol-
ogy). Eight patients had an increase in the CSF antigen titer
(four of 1 to 3 dilutions and four of 4 to 8 dilutions), and five
showed stable (i.e., the same value) results throughout the
follow-up. All the patients but two with an increase of CSF
antigen titer had persistent positive CSF culture and died; four
underwent autopsy showing disseminated cryptococcosis.
Our experience regarding the role of cryptococcal antigen to
monitor antifungal therapy in AIDS patients is in keeping with
that previously reported by Powderly et al. (11), who showed
the lack of any correlation of changes of CSF or serum cryp-
tococcal antigen and the outcome of cryptococcal meningitis.
However, a high CSF antigen level has been identified as a sign
FIG. 1. Change over time of CSF cryptococcal antigen titers and
correlation with CSF cryptococcal cultures in 66 HIV-positive patients.
Data of CSF antigen are median values. Data regarding CSF cultures
refers to the total number of patients (n  66), whereas those of CSF
antigen titer are the number of patients for whom it was available.
TABLE 1. Efficiency of different techniques in the diagnosis of cryptococcal meningitis in different hostsa
Reference Country No. ofpatients Host condition
No. positive by
CSF Ag (%)
No. positive by
CSF culture
(%)
No. positive by
India ink (%)
No. positive by
serum Ag (%)
12 Brazil 65 AIDS 3/3 (100) 65/65 (100) 61/65 (93.8) NR
4 United States 89 AIDS 80/88 (90.9) 89/89 (100) 64/87 (73.5) 70/71 (98.6)
3 Australia 128 AIDS 112/128 (87.5) 111/128 (86.7) 93/128 (72.6) NR
1 Italy 119 AIDS 112/114 (98.2) 115/118 (97.5) 84/95 (88.4) 111/112 (99.1)
Total 401 307/333 (92.2) 380/401 (94.7) 302/375 (80.5) 181/183 (98.9)
12 Brazil 44 Immunocompetent 5/6 (83.3) 26/30 (86.7) 34/44 (77.2) NR
9 Australia 31 Immunocompetent 27/31 (87.1) 26/31 (83.5) 19/31 (61.3) NR
3 Australia 41 Immunocompetent 40/41 (97.6) 39/41 (95.1) 36/41 (87.8) NR
Total 116 72/78 (92.3) 91/102 (89.2) 89/116 (76.7) 181/183 (98.9)
12 Brazil 19 HIV negative, immunocompromised NR 17/18 (94.4) 14/18 (77.8) NR
6 United States 5 Cancer patients 5/5 (100) 5/5 (100) 5/5 (100) NR
10 United States 157 HIV negative, immunocompromised 144/149 (96.6) 132/149 (89) 68/133 (51) 91/105 (87)
5 United Statesb 122 Organ transplant recipients 37/37 (100) 76/82 (93) 38/47 (77) 18/21 (86)
13 United States 28 Organ transplant recipients 28/28 (100) 21/28 (77) 14/28 (50) 20/22 (90.9)
Total 331 214/219 (97.7) 251/282 (89) 139/231 (60.2) 129/148 (87.2)
Overall total 848 593/630 (94.1) 722/785 (92) 430/722 (59.6) 310/331 (93.6)
a Ag, antigen; NR, not reported.
b Review of published reports.
5828
of poor prognosis in patients with AIDS (1, 7); interestingly,
more recently Thay cohorts of HIV-positive patients with cryp-
tococcal meningitis showed a significant positive correlation
between CSF cryptococcal colony-forming units (CFU) and
CSF cryptococcal antigen titers at baseline (P  0.0001), but
the rapid rate of decline in CSF CFU was not correlated with
that in CSF cryptococcal antigen titers (2).
As shown in Table 1, regardless of the different hosts in
whom cryptococcal meningitis is diagnosed, among all meth-
ods employed the cryptococcal CSF antigen had the best over-
all sensitivity (94.1%) followed by the serum antigen (93.6%).
However, some differences were observed in the different cat-
egories of hosts, with lower sensitivity in AIDS and immuno-
competent patients (92%) and higher sensitivity among the
other immunocompromised hosts without HIV infection. Per-
sistently elevated CSF cryptococcal antigen in HIV-infected
patients carries a poor prognosis and indicates ongoing pro-
duction of viable Cryptococcus neoformans in tissue. In conclu-
sion, CSF cryptococcal antigen seems to be the best test for
diagnosis of cryptococcal meningitis in terms of sensitivity, but
it is an unreliable tool, at least among HIV-positive patients, to
drive therapeutic monitoring, particularly in assessing the
point of discontinuation of antifungal therapy in HIV-infected
patients.
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